title: [Significance of antitumor effects and immunological response on endogenously induced LAK therapy for primary or metastatic liver tumor].
abstract: Nineteen patients with metastatic liver tumor (9 of gastric cancer, 5 of colon cancer, 2 of pancreatic cancer, one each of mammary cancer, cholecystic cancer, carcinoid of biliary tract) and one patient with primary liver cancer were treated by endogenously induced LAK therapy consisting of transhepatic arterial infusion with ADM or MMC for induction therapy and OK-432 and rIL-2 (TGP-3) for immunotherapy. The following results were obtained. 1) Clinical response for liver tumor showed no CR but 8 cases of PR, for an overall response rate of 42.1%. 2) Reduced tumor marker value was noted in 76.5% cases, and 50% survival term became 349 days after the therapy. 3) Many CD4 and CD8 positive mononuclear cells had infiltrated around liver tumor after therapy by immuno-histochemical staining of surface marker. 4) NK activity of peripheral blood lymphocytes was markedly reduced soon after the therapy and continued for about 4-7 days, while in cases of combined subcutaneous administration with OK-432, NK activity showed only a slight decrease.
authors.affiliation: 2nd Dept. of Surgery, Gifu University School of Medicine.
authors.forename: K
authors.initials: K
authors.lastname: Miya
authors.forename: S
authors.initials: S
authors.lastname: Saji
authors.forename: T
authors.initials: T
authors.lastname: Furuta
authors.forename: S
authors.initials: S
authors.lastname: Azuma
authors.forename: T
authors.initials: T
authors.lastname: Umemoto
authors.forename: H
authors.initials: H
authors.lastname: Takao
authors.forename: M
authors.initials: M
authors.lastname: Katou
authors.forename: A
authors.initials: A
authors.lastname: Kanno
authors.forename: N
authors.initials: N
authors.lastname: Kaneda
authors.forename: Y
authors.initials: Y
authors.lastname: Yamawaki
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000473:pathology; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D007694:Killer Cells, Natural / Q000276:immunology; D008113:Liver Neoplasms / Q000276:immunology / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D016685:Mitomycin / Q000008:administration & dosage; D010844:Picibanil / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000473:pathology; D015996:Survival Rate
chemical_list: D007376:Interleukin-2; D010844:Picibanil; D016685:Mitomycin; D004317:Doxorubicin